Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Dr. Christopher Manley is the Director of Interventional Pulmonology at Fox Chase Cancer Center in Philadelphia. He graduated with honors in bioethics and research from Loyola Stritch School of Medicine then completed fellowships in pulmonary/critical care at Tufts Medical Center and interventional pulmonary at the Harvard Combined (MGH/BIDMC) Program. Under Dr Manley’s leadership, Fox Chase became one of the first three hospitals in the country to develop a robotic bronchoscopy program and has remained one of the most robust robotic bronchoscopy programs in the country. Dr. Manley’s research interests include bronchoscopic imaging utilizing intra-tumoral confocal microscopy, cost-value analysis, and improving yield of small biopsy specimens. Dr. Manley is one of Philadelphia Magazine’s Top Doctors in Philadelphia and his work with the Monarch was recognized by Life Sciences Pennsylvania with the Patient Impact Award 2020.
Published in
Speakers
Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies and is the Research Director of the Center for Thoracic Cancers and the Associate Director of the Hematology/Oncology Fellowship Program at Yale. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.
Published in
Speakers
Prof. Aleš Ryška, MD, PhD, is the head of the Fingerland Department of Pathology at Charles University, Medical Faculty in Hradec Králové, Czech Republic. He received his medical degree and PhD in pathology from the Charles University, Medical Faculty. Prof. Ryška is board certified in pathology.
Prof. Ryška’s interests are in diagnostics of lesions of the breast, thyroid, and salivary glands, as well as in predictive pathology (detection of markers predicting response to targeted therapy) and quality control in pathology. He is a principal investigator and co-investigator of 17 research projects.
Prof. Ryška is a member of several scientific societies, including the International Academy of Pathology - Czech Division, the Society of Czech Pathologists, the European Society of Pathology, and the Czech Oncologic Society. He is also a member of several editorial boards of journals, including the Czech-Slovak Pathology and Forensic Medicine, Virchows Archiv, Clinical Oncology, Cytopathology, Pathology & Oncology Research. Prof. Ryška has authored and co-authored over 193 full-text articles in peer-reviewed journals, a book, and multiple book chapters.
Prof. Ryška has been an invited speaker to multiple national and international meetings (Czech Republic, Slovakia, Germany, Brazil, Hungary, Portugal, Romania, Serbia, Slovenia, Croatia, Austria, Australia, Poland, Macedonia, Jordan, Ireland, Bulgaria, France, Spain, Netherlands, UK, USA) and has tutored many courses at the European School of Pathology (thyroid gland pathology).
Prof. Ryška’s interests are in diagnostics of lesions of the breast, thyroid, and salivary glands, as well as in predictive pathology (detection of markers predicting response to targeted therapy) and quality control in pathology. He is a principal investigator and co-investigator of 17 research projects.
Prof. Ryška is a member of several scientific societies, including the International Academy of Pathology - Czech Division, the Society of Czech Pathologists, the European Society of Pathology, and the Czech Oncologic Society. He is also a member of several editorial boards of journals, including the Czech-Slovak Pathology and Forensic Medicine, Virchows Archiv, Clinical Oncology, Cytopathology, Pathology & Oncology Research. Prof. Ryška has authored and co-authored over 193 full-text articles in peer-reviewed journals, a book, and multiple book chapters.
Prof. Ryška has been an invited speaker to multiple national and international meetings (Czech Republic, Slovakia, Germany, Brazil, Hungary, Portugal, Romania, Serbia, Slovenia, Croatia, Austria, Australia, Poland, Macedonia, Jordan, Ireland, Bulgaria, France, Spain, Netherlands, UK, USA) and has tutored many courses at the European School of Pathology (thyroid gland pathology).
Published in
Speakers
Dr. Afshin Dowlati earned his medical degree from the University of Liege School of Medicine, Belgium in 1992. He then went on to complete an internal medicine residency at the same institution in Belgium and completed a second internal medicine residency and fellowship in hematology and oncology at Case Western Reserve University School of Medicine, Ohio. In 2000, he joined University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center at Case Western Reserve University, to lead the thoracic oncology program and in 2007 became Co-Leader of the Developmental Therapeutics Program.
Dr. Dowlati is the Rosalie and Morton A. Cohen Chair in Lung Cancer, the Lucile and Robert Gries Endowed Director of the Center for Lung Cancer Drug Development, and the Director of the Phase I and Thoracic Oncology programs at University Hospitals Seidman Cancer Center. Dr. Dowlati is also the Associate Director for Clinical Research at the Case Comprehensive Cancer Center. As professor of medicine and oncology at Case Western Reserve University, Dr. Dowlati’s scientific research focuses on genomics and signaling pathways in small cell lung cancer. His group was the first to describe a YAP1 positive subgroup of SCLC.
In recognition of his achievements, Dr. Dowlati has received numerous awards including being recognized as one of Cleveland Magazine’s Top Doctors for multiple years, receiving the prestigious Castle Connelly America’s Top Doctors for Cancer award on multiple occasions, and the Michaele C. Christian Oncology Drug Development Lectureship of the National Cancer Institute in 2012.
Dr. Dowlati is the Rosalie and Morton A. Cohen Chair in Lung Cancer, the Lucile and Robert Gries Endowed Director of the Center for Lung Cancer Drug Development, and the Director of the Phase I and Thoracic Oncology programs at University Hospitals Seidman Cancer Center. Dr. Dowlati is also the Associate Director for Clinical Research at the Case Comprehensive Cancer Center. As professor of medicine and oncology at Case Western Reserve University, Dr. Dowlati’s scientific research focuses on genomics and signaling pathways in small cell lung cancer. His group was the first to describe a YAP1 positive subgroup of SCLC.
In recognition of his achievements, Dr. Dowlati has received numerous awards including being recognized as one of Cleveland Magazine’s Top Doctors for multiple years, receiving the prestigious Castle Connelly America’s Top Doctors for Cancer award on multiple occasions, and the Michaele C. Christian Oncology Drug Development Lectureship of the National Cancer Institute in 2012.
Published in
Speakers
Antonio Passaro, MD, PhD, is a medical oncologist at the Division of Thoracic Oncology of the European Institute of Oncology in Milan, Italy. He received his medical degree in medicine and surgery and his PhD in molecular medicine, with a thesis on lung cancer, from the Sapienza University of Rome. Dr Passaro is board certified in medical oncology.
Dr Passaro is a clinician and translational researcher specializing in lung cancer. His main areas of research and clinical interest are predictive biomarker, in particular EGFR, and related target agents and immunotherapy agents, from discovery to validation in a clinical setting. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. Dr Passaro is also very involved and interested in using target agents in uncommon molecular patients population and non-metastatic settings, alone or in a multimodality approach for early or locally-advanced disease. He is also involved in a portfolio of many clinical trials, sponsored and academic, investigating new anticancer agents.
Dr Passaro serves in several professional societies and committees, including the ESMO Council, Chair of the ESMO Press & Media Affairs Committee and as an AIOM (Italian Association of Medical Oncology) board member for lung cancer guidelines. He has authored several peer-reviewed manuscripts, serves on the editorial board of different clinical cancer journals, and acts as a reviewer for multiple lung cancer publications.
Dr Passaro is a clinician and translational researcher specializing in lung cancer. His main areas of research and clinical interest are predictive biomarker, in particular EGFR, and related target agents and immunotherapy agents, from discovery to validation in a clinical setting. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. Dr Passaro is also very involved and interested in using target agents in uncommon molecular patients population and non-metastatic settings, alone or in a multimodality approach for early or locally-advanced disease. He is also involved in a portfolio of many clinical trials, sponsored and academic, investigating new anticancer agents.
Dr Passaro serves in several professional societies and committees, including the ESMO Council, Chair of the ESMO Press & Media Affairs Committee and as an AIOM (Italian Association of Medical Oncology) board member for lung cancer guidelines. He has authored several peer-reviewed manuscripts, serves on the editorial board of different clinical cancer journals, and acts as a reviewer for multiple lung cancer publications.
Published in
Speakers
Dr. Lisa Macera is a Senior Medical Science Liaison for Precision Oncology Medical Affairs at Exact Sciences. She holds a Ph.D. in Molecular Genetics and Microbiology from Rutgers New Jersey Medical School. Dr. Macera has held various positions as a genomics specialist and diagnostics liaison for leading technology and pharmaceutical companies. She has educated physicians and scientists on the evolving advancement of molecular technologies in diagnostics and clinical applications. Her involvement in clinical and research collaborations has her published in peer-reviewed research and medical journals.
Published in
Speakers
Dr. Snehal Thakkar is the Medical Affairs Director for Oncotype MAP at Exact Sciences. He is also a board-certified medical oncologist at Summit Healthcare’s Cancer Center and CVRMC. Dr. Snehal Thakkar individualizes each patient’s treatment plan to fit their specific healthcare needs. Dr. Thakkar is board certified in medical oncology, hematology, and internal medicine. He is a member of the American Society of Clinical Oncology and American Society of Hematology. Throughout his career, Dr. Thakkar has been involved in several research programs as a co-investigator and published in peer review medical journals. He has presented to his peers at national oncology conferences.
Published in
Speakers
Published in
Speakers
Prof. Nobuyuki Takakura is Professor at the Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan. He gained his MD in 1988 at the Mie University Faculty of Medicine and his PhD in 1997 at the Graduate School of Medicine, Kyoto University, Japan. He was a physician at the Department of Internal Medicine, Mie University between 1988 and 1993. He was an instructor then assistant professor at the Institute of Molecular Embryology and Genetics, Kumamoto University between 1997 and 2000 followed by Professor at the Cancer Research Institute, Kanazawa University between 2001 and 2006. He is the author or co-author of more than 130 papers in peer-review journals.
Published in
Speakers
Published in
Speakers
